/PRNewswire/ HistoIndex has announced that its novel technology combining Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging with Artificial.
/PRNewswire/ HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis®.
/PRNewswire/ HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a.
Share this article
Share this article
HistoIndex joins forces with a consortium of partners from NHS Health Boards, UK universities and technology companies for the development of a novel AI-based integrated diagnostic tool.
There is currently no available method to accurately identify patients with NAFLD who are at a higher risk of developing a more progressive form of liver disease (non-alcoholic steatohepatitis or NASH) that can lead to cirrhosis, liver cancer and premature death. NASH is an unmet liver condition that awaits an FDA-approved treatment.
Having an AI-based diagnostics tool that provides a fully quantitative and accurate assessment of fibrosis will provide clinicians with a deeper understanding of the disease and its progressive features, which will aid in enrolling high-risk patients for NASH clinical trials.